How a data analytics & AI partner adds value to biotech and pharma – according to Liesbeth Ceelen

Liesbeth Ceelen is the CEO of BioLizard and a mother of three. Before she put her shoulders under the BioLizard project, she had quite the journey…
For just one project at the intersection of data science and biology, you might require expertise spanning from the deep understanding of multi-omics and bioinformatics analysis, to applied skills in software engineering and data architecture and governance. At BioLizard, we’re dedicated to fostering this deep and broad expertise in our team of Lizards - and we’ve collected that knowledge here for you to explore.
Biomarkers come in many shapes and sizes. It’s an ever-evolving subject with many under-discovered possibilities. Let’s look at some ways biomarkers are likely to evolve. Whether we’re talking about how to gather data, how to analyse the collected data, or new ways to conduct your newly developed ...
Developing a biomarker – either for diagnosis or supporting drug development – is a costly and time-consuming process. Over the years, we’ve built up reliable experience concerning this topic. That’s why in this blog, we’ll share three rules to remember when developing biomarkers: one during ...
Discovering a strong biomarker is an expensive and time-consuming process. One of the key takeaways is to take your time and look at the data before you start testing for biomarkers. Why? Because junk in equals junk out. You can run the best models and the most advanced statistical analysis. But ...